File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay

TitleEvidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
Authors
KeywordsHBcrAg
HBsAg
Linearized HBsAg
Seroclearance
Serology
Issue Date2013
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
Hepatology International, 2013, v. 7 n. 1, p. 98-105 How to Cite?
Abstract
Background: Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance documented by conventional assays in chronic hepatitis B (CHB) has not been thoroughly investigated. Methods: We determined the levels of serum hepatitis B virus (HBV) DNA, hepatitis B core-related antigen (HBcrAg), and linearized HBsAg (CLEIA prototype) in 329 CHB patients (72.0% male) after HBsAg seroclearance was documented by a conventional HBsAg assay. Results: The median interval between presentation and HBsAg seroclearance was 69.4 months. The median age at HBsAg seroclearance was 50 years. Assays for serum HBV DNA, HBcrAg, and linearized HBsAg were performed at a median time interval of 11.2 months after HBsAg loss. Linearized HBsAg and HBcrAg were detectable in 85 (25.8%) and 69 (21%) patients, respectively, and one or both serologic markers were detectable in 133 patients (40.4%). Serum HBV DNA was detectable in only 7 patients (2.1%). There was no correlation between linearized HBsAg and HBcrAg levels (r = 0.095, p = 0.924). The incidences of detectable linearized HBsAg and HBcrAg did not differ between patient samples taken at 6-12 and >12 months after HBsAg seroclearance (p = 0.146 and 0.079, respectively). Among patients with detectable serologic markers, median levels of linearized HBsAg (p = 0.581) and HBcrAg (p = 0.951) did not significantly change with time after HBsAg seroclearance. Conclusion: Using novel HBcrAg and linearized HBsAg assays, viral serologic activity after HBsAg seroclearance was demonstrated in more than 40% of CHB patients. These tests have potential applications in diagnosing and prognosticating CHB patients with HBsAg seroclearance. © 2012 Asian Pacific Association for the Study of the Liver.
Persistent Identifierhttp://hdl.handle.net/10722/163465
ISSN
2013 Impact Factor: 2.468
ISI Accession Number ID

 

Author Affiliations
  1. Nagoya City University
  2. The University of Hong Kong
DC FieldValueLanguage
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorTanaka, Yen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorShinkai, Nen_HK
dc.contributor.authorYuen, JCHen_HK
dc.contributor.authorTong, Ten_HK
dc.contributor.authorFung, Jen_HK
dc.contributor.authorHung, IFNen_HK
dc.contributor.authorYuen, MFen_HK
dc.date.accessioned2012-09-05T05:31:43Z-
dc.date.available2012-09-05T05:31:43Z-
dc.date.issued2013en_HK
dc.identifier.citationHepatology International, 2013, v. 7 n. 1, p. 98-105en_HK
dc.identifier.issn1936-0533en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163465-
dc.description.abstractBackground: Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance documented by conventional assays in chronic hepatitis B (CHB) has not been thoroughly investigated. Methods: We determined the levels of serum hepatitis B virus (HBV) DNA, hepatitis B core-related antigen (HBcrAg), and linearized HBsAg (CLEIA prototype) in 329 CHB patients (72.0% male) after HBsAg seroclearance was documented by a conventional HBsAg assay. Results: The median interval between presentation and HBsAg seroclearance was 69.4 months. The median age at HBsAg seroclearance was 50 years. Assays for serum HBV DNA, HBcrAg, and linearized HBsAg were performed at a median time interval of 11.2 months after HBsAg loss. Linearized HBsAg and HBcrAg were detectable in 85 (25.8%) and 69 (21%) patients, respectively, and one or both serologic markers were detectable in 133 patients (40.4%). Serum HBV DNA was detectable in only 7 patients (2.1%). There was no correlation between linearized HBsAg and HBcrAg levels (r = 0.095, p = 0.924). The incidences of detectable linearized HBsAg and HBcrAg did not differ between patient samples taken at 6-12 and >12 months after HBsAg seroclearance (p = 0.146 and 0.079, respectively). Among patients with detectable serologic markers, median levels of linearized HBsAg (p = 0.581) and HBcrAg (p = 0.951) did not significantly change with time after HBsAg seroclearance. Conclusion: Using novel HBcrAg and linearized HBsAg assays, viral serologic activity after HBsAg seroclearance was demonstrated in more than 40% of CHB patients. These tests have potential applications in diagnosing and prognosticating CHB patients with HBsAg seroclearance. © 2012 Asian Pacific Association for the Study of the Liver.en_HK
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0en_HK
dc.relation.ispartofHepatology Internationalen_HK
dc.subjectHBcrAgen_HK
dc.subjectHBsAgen_HK
dc.subjectLinearized HBsAgen_HK
dc.subjectSeroclearanceen_HK
dc.subjectSerologyen_HK
dc.titleEvidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assayen_HK
dc.typeArticleen_HK
dc.identifier.emailSeto, WK: wkseto2@hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityHung, IFN=rp00508en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s12072-012-9354-7en_HK
dc.identifier.scopuseid_2-s2.0-84875241425en_HK
dc.identifier.hkuros213662-
dc.identifier.spage98en_HK
dc.identifier.epage105en_HK
dc.identifier.isiWOS:000316350600012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.scopusauthoridTanaka, Y=7405315865en_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridShinkai, N=7003826116en_HK
dc.identifier.scopusauthoridYuen, JCH=7102620480en_HK
dc.identifier.scopusauthoridTong, T=7102587364en_HK
dc.identifier.scopusauthoridFung, J=55032286400en_HK
dc.identifier.scopusauthoridHung, IFN=7006103457en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.citeulike10463261-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats